[1] Ginès P, Krag A, Abraldes J G, et al. Liver cirrhosis[J]. Lancet, 2021, 398(10308): 1359-1376.
[2] Seo Y S. Prevention and management of gastroesophageal varices[J]. Clin Mol Hepatol,2018, 24(1): 20.
[3] Garcia-Tsao G, Abraldes J G, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335.
[4] Reverter E, Tandon P, Augustin S, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding[J]. Gastroenterology, 2014, 146(2): 412-419. e3.
[5] Fabbian F, Cappadona R, Guarino M, et al. Sex and acute oesophageal variceal bleeding-related in-hospital mortality: a 15-year retrospective study[J]. Eur Rev Med Pharmacol Sci, 2019, 23(2):811-817.
[6] Koh C, Heller T, Glenn J S. Pathogenesis of and new therapies for hepatitis D[J]. Gastroenterology, 2019, 156(2): 461-476. e1.
[7] Yuen M F, Chen D S, Dusheiko G M, et al. Hepatitis B virus infection[J]. Nat Rev Dis Primers, 2018, 4(1): 1-20.
[8] Iannacone M, Guidotti L G. Immunobiology and pathogenesis of hepatitis B virus infection[J]. Nat Rev Immunol, 2022, 22(1): 19-32.
[9] Zhang Y Y, Hu K Q. Rethinking the pathogenesis of hepatitis B virus (HBV) infection[J]. J Med Virol, 2015, 87(12): 1989-1999.
[10] Manns M P, Buti M, Gane E D, et al. Hepatitis C virus infection[J]. Nat Rev Dis Primers, 2017, 3(1): 1-19.
[11] Pisano M B, Giadans C G, Flichman D M, et al. Viral hepatitis update: progress and perspectives[J]. World J Gastroenterol, 2021, 27(26): 4018.
[12] Nguyen M H, Wong G, Gane E, et al. Hepatitis B virus: advances in prevention, diagnosis, and therapy[J]. Clin Microbiol Rev, 2020, 33(2): e00046-19.
[13] Suzuki F, Hosaka T, Suzuki Y, et al. Long-term outcome of entecavir treatment of nucleos (t) ide analogue-na?ve chronic hepatitis B patients in Japan[J]. J Gastroenterol, 2019, 54: 182-193.
[14] Yardeni D, Chang K M, Ghany M G. Current best practice in hepatitis B management and understanding long-term prospects for cure[J]. Gastroenterology, 2023, 164(1): 42-60. e6.
[15] Manns M P, Maasoumy B. Breakthroughs in hepatitis C research: from discovery to cure[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(8): 533-550.
[16] Moon A M, Green P K, Rockey D C, et al. Hepatitis C eradication with direct-acting anti‐virals reduces the risk of variceal bleeding[J]. Aliment Pharmacol Ther, 2020, 51(3): 364-373.
[17] Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease[J]. Gut, 2021, 70(9): 1782-1794.
[18] Koh C, Heller T, Glenn J S. Pathogenesis of and new therapies for hepatitis D[J]. Gastroenterology, 2019, 156(2): 461-476. e1.
[19] Lee H W, Park J Y, Kim S G, et al. Long-term outcomes of antiviral therapy in patients with advanced chronic HBV infection[J]. Clin Gastroenterol Hepatol, 2019, 17(13): 2811-2813. e1.
[20] Kumada T, Toyoda H, Yasuda S, et al. Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis[J]. J Viral Hepat, 2021, 28(9): 1293-1303.
[21] Seitz H K, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease[J]. Nat Rev Dis Primers, 2018, 4(1): 16.
[22] Hyun J, Han J, Lee C, et al. Pathophysiological aspects of alcohol metabolism in the liver[J]. Int J Mol Sci, 2021, 22(11): 5717.
[23] Kim Y S, Kim S G. Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases[J]. Clin Mol Hepatol, 2020, 26(4): 715-727.
[24] Bajaj J S. Alcohol, liver disease and the gut microbiota[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(4): 235-246.
[25] Tadokoro T, Morishita A, Himoto T, et al. Nutritional support for alcoholic liver disease[J]. Nutrients, 2023, 15(6): 1360.
[26] He Q, Yang C, Kang X, et al. Intake of Bifidobacterium lactis Probio-M8 fermented milk protects against alcoholic liver disease[J]. J Dairy Sci, 2022, 105(4): 2908-2921.
[27] Wang Q, Kim S Y, Matsushita H, et al. Oral administration of PEGylated TLR7 ligand ameliorates alcohol-associated liver disease via the induction of IL-22[J]. Proc Natl Acad Sci U S A, 2021, 118(1): e2020868118.
[28] Bennett K, Enki D G, Thursz M, et al. Systematic review with meta‐analysis: high mortality in patients with non-severe alcoholic hepatitis[J]. Aliment Pharmacol Ther, 2019, 50(3): 249-257.
[29] Penninti P, Adekunle A D, Singal A K. Alcoholic hepatitis: the rising epidemic[J]. Med Clin North Am, 2023, 107(3): 533-554.
[30] Gustot T, Jalan R. Acute-on-chronic liver failure in patients with alcohol-related liver disease[J]. J Hepatol, 2019, 70(2): 319-327.
[31] Eslam M, Sarin S K, Wong V W S, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020, 14: 889-919.
[32] Powell E E, Wong V W S, Rinella M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224.
[33] Park J, Zhao Y, Zhang F, et al. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease[J]. J Hepatol, 2023, 78(1): 45-56.
[34] Mitten E K, Baffy G. Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease[J]. J Hepatol, 2022, 77(6): 1642-1656.
[35] Kobayashi T, Iwaki M, Nakajima A, et al. Current research on the pathogenesis of NAFLD/NASH and the gut-liver axis: gut microbiota, dysbiosis, and leaky-gut syndrome[J]. Int J Mol Sci, 2022, 23(19): 11689.
[36] Ezpeleta M, Gabel K, Cienfuegos S, et al. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: a randomized controlled trial[J]. Cell Metab, 2023, 35(1): 56-70. e3.
[37] Lei Y, Tang L, Chen Q, et al. Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism[J]. Nat Commun, 2022, 13(1): 6862.
[38] Targher G, Byrne C D, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications[J]. Gut, 2020, 69(9): 1691-1705.
[39] Park J, Kim G, Kim H, et al. The association of hepatic steatosis and fibrosis with heart failure and mortality[J]. Cardiovasc Diabetol, 2021, 20(1): 197.
[40] Nakashima M, Nakamura K, Nishihara T, et al. Association between cardiovascular Disease and liver disease, from a clinically pragmatic perspective as a cardiologist[J]. Nutrients, 2023, 15(3): 748.
[41] Lleo A, Wang G Q, Gershwin M E, et al. Primary biliary cholangitis[J]. Lancet, 2020, 396(10266): 1915-1926.
[42] Li H, Guan Y, Han C, et al. The pathogenesis, models and therapeutic advances of primary biliary cholangitis[J]. Biomed Pharmacother, 2021, 140: 111754.
[43] Gulamhusein A F, Hirschfield G M. Primary biliary cholangitis: pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2): 93-110.
[44] Ezhilarasan D. Hepatic stellate cells in the injured liver: perspectives beyond hepatic fibrosis[J]. J Cell Physiol, 2022, 237(1): 436-449.
[45] Levy C, Manns M, Hirschfield G. New treatment paradigms in primary biliary cholangitis[J]. Clin Gastroenterol Hepatol, 2023, 21(8): 2076-2087.
[46] Perez C F M, Fisher H, Hiu S, et al. Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls[J]. Gastroenterology, 2022, 163(6): 1630-1642. e3.
[47] John B V, Khakoo N S, Schwartz K B, et al. Ursodeoxycholic acid response is associated with reduced mortality in primary biliary cholangitis with compensated cirrhosis[J]. Am J Gastroenterol, 2021, 116(9): 1913-1923.
[48] John B V, Aitcheson G, Schwartz K B, et al. Male sex is associated with higher rates of liver‐related mortality in primary biliary cholangitis and cirrhosis[J]. Hepatology, 2021, 74(2): 879-891. |
